secwatch.observer — SEC 8-K summary
======================================

Issuer:     IDEAYA Biosciences, Inc. (IDYA)
CIK:        0001676725
Form:       8-K
Filed at:   2024-02-20T23:59:59+00:00
Accession:  0000950170-24-016758
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IDYA reports Q4 net loss $34M, cash $632.6M; multiple 2024 milestones
---------------------------------------------------------------------

- Cash $632.6M at Dec 31, 2023; Jan 2024 ATM raised ~$352M gross ($342.3M net); runway into 2028.
- Q4 net loss $34.0M (vs $24.2M); FY 2023 net loss $113.0M (vs $58.7M). R&D spend $38.8M Q4.
- Targeting two Phase 2 efficacy updates for darovasertib in neoadjuvant uveal melanoma mid-2024, plus FDA guidance.
- Gilead collaboration to evaluate IDE397 + Trodelvy in MTAP-deletion bladder cancer; FPI mid-2024.
- Werner helicase IND filing targeted 2024; $7M milestone on clearance. GSK collaboration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1676725/000095017024016758/0000950170-24-016758-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1676725/000095017024016758/idya-20240220.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-016758

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer